Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anacor’s Tavaborole May Lag Valeant’s Competing Antifungal In Both Efficacy And Approval Time

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Anacor released positive top-line Phase III data for the most advanced of its boron-based anti-infectives, the antifungal tavaborole, but the results weren’t good enough for some shareholders who were looking for the compound to best Valeant’s antifungal, currently pending at FDA with a May action date.

You may also be interested in...

GSK Ends Deal For Anacor’s Antibiotic, Returns Rights

The pharma ended the deal after halting studies on an antibiotic for Gram-negative bacterial infections when some clinical patients showed evidence of microbiological resistance.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.

Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal

President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts